Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Cagrilintide research reference →
103 records · showing 25 · open this search in PubMed
- PubMedReviewResearch Support, Non-U.S. Gov'tAmylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet (London, England) · 2026 Dec 20
- PubMedCo-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.Physiology & behavior · 2026 Nov 1
- PubMedDesign and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).American heart journal · 2026 Oct 6
- PubMedSystematic ReviewMeta-AnalysisCagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.Frontiers in endocrinology · 2026
- PubMedReviewGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026 Oct
- PubMedCagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nature metabolism · 2026 Oct
- PubMedSystematic ReviewReviewEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Annals of internal medicine · 2026 Oct
- PubMedReviewBeyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.Pharmacological research · 2026 Oct
- PubMedRandomized Controlled TrialEfficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2026 Oct
- PubMedReviewNew Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 28
- PubMedEfficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
- PubMedReviewRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
- PubMedRandomized Controlled TrialClinical Trial, Phase IIMulticenter StudyEfficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.The lancet. Gastroenterology & hepatology · 2026 Sep
- PubMedReviewAmylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.Diabetes, obesity & metabolism · 2026 Sep
- PubMedMeta-AnalysisSystematic ReviewWeight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring, Md.) · 2026 Sep
- PubMedComparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.BMJ medicine · 2026
- PubMedReviewMaximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026 Aug 17
- PubMedAmylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026 Aug
- PubMedDistinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.Nature metabolism · 2026 Aug
- PubMedSystematic ReviewNetwork Meta-AnalysisBenefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Annals of internal medicine · 2026 Aug
- PubMedRandomized Controlled TrialClinical Trial, Phase IIIMulticenter StudyEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026 Aug
- PubMedRandomized Controlled TrialClinical Trial, Phase IIIMulticenter StudyCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026 Aug
- PubMedCagrilintide-semaglutide: a new option for patients with type 2 diabetes.The lancet. Diabetes & endocrinology · 2026 Aug
- PubMedReviewBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · 2026 Aug
- PubMedSystematic ReviewNetwork Meta-AnalysisComparative StudyComparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2026 Jul 8
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.